title: Massive intra-abdominal imatinib-resistant gastrointestinal stromal tumor in a 21-year-old male.
abstract: Gastrointestinal stromal tumors (GISTs) in adolescence are far less common than adult GISTs and have varied GIST genotypes that present diagnostic and therapeutic challenges. Here, we discuss a 21-year-old male with diagnosis of unresectable, imatinib-resistant GIST. At initial evaluation, a neoadjuvant treatment approach was recommended. As such, the patient received imatinib over the course of one year. Unfortunately, the GIST increased in size, and a subsequent attempt at surgical resection was aborted fearing infiltration of major vascular structures. The patient was then referred to our institution, at which time imatinib therapy was discontinued. Surgical intervention was again considered and the patient underwent successful resection of massive intra-abdominal GIST with total gastrectomy and Roux-en-Y esophagojejunostomy. Since pediatric GISTs are typically resistant to imatinib, we performed genotype analysis of the operative specimen that revealed KIT mutations associated with imatinib sensitivity and resistance. Given the sequencing data and operative findings, the patient was started postoperatively on sunitinib. This case illustrates the importance of understanding both adult and pediatric GISTs when implementing appropriate treatment regimens. Since the genotype of GISTs dictates phenotypic behavior, mutational analysis is an important component of care especially for adolescents whose disease may mirror the pediatric or adult population.
authors: Department of Surgery, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509, USA.
authors: Ann
authors: A
authors: Falor
authors: Amanda K
authors: AK
authors: Arrington
authors: Carrie
authors: C
authors: Luu
authors: Hans F
authors: HF
authors: Schoellhammer
authors: Michelle
authors: M
authors: Ko
authors: Warren
authors: W
authors: Chow
authors: Massimo
authors: M
authors: D'Apuzzo
authors: Jinha
authors: J
authors: Park
authors: Joseph
authors: J
authors: Kim
references: Mol Cancer Ther. 2012 Aug;11(8):1770-80
references: 22665524
references: Ann Surg Oncol. 2007 Feb;14(2):526-32
references: 17139461
references: Invest New Drugs. 2012 Dec;30(6):2377-83
references: 22270258
references: J Pathol. 2008 Sep;216(1):64-74
references: 18623623
references: J Clin Oncol. 2003 Dec 1;21(23):4342-9
references: 14645423
references: J Surg Oncol. 2011 Dec;104(8):928-32
references: 22069178
references: Hematol Oncol Clin North Am. 2009 Feb;23(1):15-34, vii
references: 19248968
references: J Clin Oncol. 2008 Feb 1;26(4):620-5
references: 18235121
references: Ann Surg Oncol. 2009 Apr;16(4):910-9
references: 18953611
references: Mol Cancer Ther. 2005 Dec;4(12):2008-15
references: 16373716
references: Ann Surg Oncol. 2012 Apr;19(4):1074-80
references: 22203182
references: Pediatr Blood Cancer. 2009 Jul;52(7):767-71
references: 19326424
references: Eur J Cancer. 2004 Mar;40(5):689-95
references: 15010069
references: J Clin Oncol. 2006 May 20;24(15):2325-31
references: 16710031
references: N Engl J Med. 2007 Jan 11;356(2):125-34
references: 17215530
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30
references: 17624289
references: Clin Cancer Res. 2005 Jun 1;11(11):4182-90
references: 15930355
references: J Clin Oncol. 2004 Sep 15;22(18):3813-25
references: 15365079
references: Pediatr Blood Cancer. 2009 Dec 15;53(7):1171-9
references: 19499582
references: J Natl Compr Canc Netw. 2012 Dec 1;10(12):1477-82; quiz 1482
references: 23221786